Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31011078 | 0.84 | — | — | |
| SCHEMBL3582413 | 0.81 | L3MBTL1 (0.55) | L3MBTL1TSHRALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL2184936 | 0.80 | ATM (0.50) | L3MBTL1TSHRSMN1; SMN2POLBGAA | |
| SCHEMBL9723709 | 0.80 | L3MBTL1 (0.50) | L3MBTL1TSHRALOX15HSD17B10MAPT | |
| SCHEMBL27734669 | 0.79 | L3MBTL1 (0.53) | L3MBTL1TSHRALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL5315426 | 0.78 | ATM (0.48) | L3MBTL1TSHRSMN1; SMN2GAALMNA | |
| SCHEMBL9053395 | 0.78 | MAPT (0.48) | L3MBTL1TSHRHSD17B10MAPTSMN1; SMN2 | |
| SCHEMBL5312699 | 0.78 | ATM (0.48) | L3MBTL1TSHRSMN1; SMN2GAALMNA | |
| SCHEMBL2186918 | 0.78 | ATM (0.48) | L3MBTL1TSHRSMN1; SMN2GAALMNA | |
| SCHEMBL27755282 | 0.78 | L3MBTL1 (0.52) | L3MBTL1TSHRALOX15HSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346507-A1 | USE OF QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | Boehringer Ingelheim International GmbH (DE) | 2011-07-27 | — | — | EP | claimed |
| EP-2268716-A1 | FLEXIBLE HARDCOATS AND SUBSTRATES COATED THEREWITH | Momentive Performance Materials Inc. (US) | 2011-01-05 | — | — | EP | claimed |
| WO-2010026029-A1 | USE OF QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-11 | — | — | WO | claimed |
| US-20090269504-A1 | Flexible hardcoats and substrates coated therewith | MOMENTIVE PERFORMANCE MATERIALS INC. | 2009-10-29 | — | — | US | claimed |
| WO-2009131680-A1 | FLEXIBLE HARDCOATS AND SUBSTRATES COATED THEREWITH | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2009-10-29 | — | — | WO | claimed |
| EP-0071433-A1 | Medicine for the treatment of diabetes | KOWA COMPANY, LTD. (JP) | 1983-02-09 | — | — | EP | claimed |
| EP-3357943-B1 | MODIFIED CONJUGATED DIENE-BASED POLYMER AND METHOD OF PREPARING THE SAME | LG CHEMICAL LTD (KR) | 2022-07-20 | — | — | EP | disclosed |
| US-11384033-B2 | Compositions with improved urease-inhibiting effect comprising (thio)phosphoric acid triamide and further compounds such as amines and colorants | BASF SE (DE) | 2022-07-12 | — | — | US | disclosed |
| EP-3939968-A1 | NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME | Medicinal Bioconvergence Research Center (KR) | 2022-01-19 | — | — | EP | disclosed |
| CN-107108388-B | Composition comprising (thio) phosphoric triamide and other compounds such as amines and colorants with improved urease-inhibiting effect | 巴斯夫欧洲公司 | 2021-02-26 | — | — | CN | disclosed |
| CN-112374933-A | Composition comprising (thio) phosphoric triamide and other compounds such as amines and colorants with improved urease-inhibiting effect | 巴斯夫欧洲公司 | 2021-02-19 | — | — | CN | disclosed |
| EP-3763691-A1 | COMPOSITIONS WITH IMPROVED UREASE-INHIBITING EFFECT COMPRISING (THIO)PHOSPHORIC ACID TRIAMIDE AND FURTHER COMPOUNDS SUCH AS AMINES AND COLORANTS | BASF SE (DE) | 2021-01-13 | — | — | EP | disclosed |
| EP-3763692-A1 | COMPOSITIONS WITH IMPROVED UREASE-INHIBITING EFFECT COMPRISING (THIO) PHOSPHORIC ACID TRIAMIDE AND FURTHER COMPOUNDS SUCH AS AMINES AND COLORANTS | BASF SE (DE) | 2021-01-13 | — | — | EP | disclosed |
| EP-1729754-B1 | SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF HOT FLASHES | LILLY CO ELI (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20070083046-A1 | Morpholine derivatives as norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY (US) | 2007-04-12 | — | — | US | disclosed |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | ELI LILY AND COMPANY (US) | 2007-01-18 | — | — | US | disclosed |
| EP-1682523-A1 | MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-07-26 | — | — | EP | disclosed |
| CN-1255383-C | Multifunctional alkoxyamines based on polyalkylpiperidines, polyalkylpiperazinones and polyalkylmorpholinones and their use as polymerization regulators/initiators | CIBA SC HOLDING AG (CH) | 2006-05-10 | — | — | CN | disclosed |
| WO-2005047272-A1 | MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-05-26 | — | — | WO | disclosed |
| CN-1522247-A | Multifunctional alkoxyamines based on polyalkylpiperidines, polyalkylpiperazinones and polyalkylmorpholinones and their use as polymerization regulators/initiators | �������⻯ѧƷ�ع�����˾ | 2004-08-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384033-B2 | Compositions with improved urease-inhibiting effect comprising (thio)phosphoric acid triamide and further compounds such as amines and colorants | SLC14A1, XDH, PNP | L3MBTL1 1577/4885TSHR 652/4885ALOX15 1666/4885 |
| US-20070083046-A1 | Morpholine derivatives as norepinephrine reuptake inhibitors | SLC6A2, SLC18A2, SLC6A3 | L3MBTL1 3071/4885TSHR 1375/4885ALOX15 2431/4885 |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | SLC6A2, SLC6A4, HTR5A | L3MBTL1 3499/4885TSHR 496/4885ALOX15 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.